"The two companies are valued at $83 billion and $60 billion respectively, which will likely draw scrutiny from hawkish regulators. Our experts were dubious as to whether Humana would be allowed to buy Cigna's Medicare Advantage business, let alone embark on a fully fledged merger," Third Bridge senior analyst George Congdon told Business Insider.